Insmed Inc(INSM-Q)NASDAQ
Today's Change
Real-Time Last Update
Pre Market Change
Pre Market Last Update
Volume
Sectors & Indices
Sector
Industry
Employees
Profile
Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
Key Executives
| Name | Title |
|---|---|
| S. Nicole Schaeffer | Other Executive Officer |
| William H. Lewis | CEO/Chairman of the Board/Director/President |
| Sara Bonstein | CFO/Chief Accounting Officer |
| Drayton Wise | Other Executive Officer |
| Roger Adsett | COO |
| Martina Flammer | Chief Medical Officer |
| Michael A. Smith | Chief Legal Officer/General Counsel/Secretary/Senior VP |